Sterile Processing

Many infectious pathogens are difficult to treat because they develop into biofilms, layers of metabolically active but slowly growing bacteria embedded in a protective layer of slime, which are inherently more resistant to antibiotics. Now, a group of researchers at Caltech and the University of Oxford have made progress in the fight against biofilms. Led by Dianne Newman, the Gordon M. Binder/Amgen Professor of Biology and Geobiology, the group identified a protein that degrades and inhibits biofilms of Pseudomonas aeruginosa, the primary pathogen in cystic fibrosis (CF) infections.

To help address the tough questions related to its inquiry into third-party servicing and refurbishment of medical devices, the Food and Drug Administration (FDA) scheduled a two-day public workshop for late October. Stakeholders are many and quite diverse, ranging from clinicians, patient safety managers and HTM professionals, to original equipment manufacturers (OEMs) and those aforementioned third-party firms; all of whom will be providing their perspectives on how to ensure patient safety while controlling costs in an environment where organizations vary in how they repair and generally maintain devices.

Princeton researchers have for the first time revealed the mechanics of how bacteria build up slimy masses, called biofilms, cell by cell. When encased in biofilms in the human body, bacteria are a thousand times less susceptible to antibiotics, making certain infections, such as pneumonia, difficult to treat and potentially lethal.